Literature DB >> 18374150

Interleukin-4 induces lipogenesis in porcine endothelial cells, which in turn is critical for induction of protection against complement-mediated injury.

S M Black1, M E Schott, B A Benson, M S Rutherford, B K Levay Young, A P Dalmasso.   

Abstract

Interleukin (IL)-4 has been shown to induce protection in porcine vascular endothelial cells (ECs) from killing by human complement. This protection is dependent on the PI3K/Akt signaling pathway. In this study, we investigated mechanisms downstream of Akt and found that activation of the lipid biosynthesis pathway is required for protection from complement in ECs treated with IL-4. Cells incubated with IL-4 for 48 hours contained increased fatty acids and phospholipids but cholesterol was not increased when compared with medium-treated controls. The transcription factor SREBP-1, which regulates fatty acid synthesis, was found to be activated in extracts of ECs incubated with IL-4 for 6 hours. Finally, induction of protection from complement killing with IL-4 was fully prevented by the presence of the SREBP inhibitor 25-OH cholesterol. This study showed that IL-4 induces lipid biosynthesis in porcine ECs through activation of SREBP-1 and that the activation of this pathway is critical for IL-4 to induce protection of porcine ECs from killing by human complement. Further study of these mechanisms may provide new strategies for the prevention of complement-mediated vascular injury as it occurs in xenograft rejection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374150      PMCID: PMC2637761          DOI: 10.1016/j.transproceed.2008.02.013

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  12 in total

1.  Resealing of large transmembrane pores produced by streptolysin O in nucleated cells is accompanied by NF-kappaB activation and downstream events.

Authors:  Iwan Walev; Michael Hombach; Wieslawa Bobkiewicz; Dominic Fenske; Sucharit Bhakdi; Matthias Husmann
Journal:  FASEB J       Date:  2001-12-14       Impact factor: 5.191

2.  IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway.

Authors:  John F Grehan; Brett K Levay-Young; Jeremy L Fogelson; Vanessa François-Bongarçon; Barbara A Benson; Agustin P Dalmasso
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

3.  Heme oxygenase-1: a therapeutic amplification funnel.

Authors:  Fritz H Bach
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

4.  Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O.

Authors:  I Walev; S C Bhakdi; F Hofmann; N Djonder; A Valeva; K Aktories; S Bhakdi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

5.  PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP.

Authors:  Thomas Porstmann; Beatrice Griffiths; Yuen-Li Chung; Oona Delpuech; John R Griffiths; Julian Downward; Almut Schulze
Journal:  Oncogene       Date:  2005-09-29       Impact factor: 9.867

6.  Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival.

Authors:  Laure Gurcel; Laurence Abrami; Stephen Girardin; Jurg Tschopp; F Gisou van der Goot
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

7.  Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis.

Authors:  Ximing Du; Ika Kristiana; Jenny Wong; Andrew J Brown
Journal:  Mol Biol Cell       Date:  2006-03-29       Impact factor: 4.138

Review 8.  The activation of Akt/PKB signaling pathway and cell survival.

Authors:  Gang Song; Gaoliang Ouyang; Shideng Bao
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

9.  A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation.

Authors:  Soizic Daniel; Maria B Arvelo; Virendra I Patel; Christopher R Longo; Gautam Shrikhande; Tala Shukri; Jerome Mahiou; David W Sun; Christina Mottley; Shane T Grey; Christiane Ferran
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

10.  Vascular endothelial growth factor activation of sterol regulatory element binding protein: a potential role in angiogenesis.

Authors:  Rui-Hai Zhou; Min Yao; Tzong-Shyuan Lee; Yi Zhu; Manuela Martins-Green; John Y-J Shyy
Journal:  Circ Res       Date:  2004-07-22       Impact factor: 17.367

View more
  5 in total

1.  Protection of porcine endothelial cells against apoptosis with interleukin-4.

Authors:  Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

2.  Interleukin-4 induces up-regulation of endothelial cell claudin-5 through activation of FoxO1: role in protection from complement-mediated injury.

Authors:  Agustin P Dalmasso; Daniel Goldish; Barbara A Benson; Alexander K Tsai; Karen R Wasiluk; Gregory M Vercellotti
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

3.  IL-4 and IL-13 induce protection from complement and melittin in endothelial cells despite initial loss of cytoplasmic proteins: membrane resealing impairs quantifying cytotoxicity with the lactate dehydrogenase permeability assay.

Authors:  Barbara A Benson; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2015-06-01       Impact factor: 3.907

4.  On the intersections of basic and applied research in xenotransplantation.

Authors:  Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

5.  Interleukin-4-induced FABP4 promotes lipogenesis in human skeletal muscle cells by activating the PPAR γ signaling pathway.

Authors:  Xin-Wen Wang; Yong-Jin Sun; Xiao Chen; Wen-Zhi Zhang
Journal:  Cell Biochem Biophys       Date:  2022-02-04       Impact factor: 2.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.